mRNA治療薬の開発・製造受託機関の市場規模、シェア、動向分析レポート：適応症別、用途別、最終用途別、地域別、セグメント予測、2025年～2033年

mRNA治療薬の開発・製造受託機関市場の成長と動向

Grand View Research, Inc.の最新レポートによると、mRNA治療薬の開発・製造受託機関の世界市場規模は2033年までに147億5,000万米ドルに達し、2025～2033年のCAGRは15.22％で拡大すると推定されています。

mRNAと細胞送達システムの技術的進歩の高まりは、その費用対効果、製造の簡便さ、以前は治療不可能であった経路を標的とする能力と相まって、医療に革命をもたらす無限の可能性を秘めています。これは市場にとって有利な成長機会となりえます。mRNA治療を開発するための研究開発投資の増加と強力な製品パイプラインも、市場の成長を後押ししています。例えば、Modernaは、2023年第4四半期の研究開発費が2022年同期比16%増の14億米ドルに達したと発表しました。

研究開発費は、同社のサイトメガロウイルス（CMV）ワクチン、RSVワクチン、COVID-19とインフルエンザに対する混合ワクチン、個別化ネオアンチゲン療法による臨床製造活動の増加によってもたらされました。このような要因がmRNA治療薬の調査努力を後押しすると予想されます。さらに、アンメットメディカルニーズに対応するための新規治療の開発が、製品市場を変化させています。分子の複雑さが増すにつれ、研究と製造サービスにおける深い知識、ならびに新規分子フォーマットのサステイナブル発現とスケールアップを可能にする技術の必要性が高まっています。バイオコンジュゲーションや二重特異性抗体の作製などのプラットフォーム技術は、開発期間や生産期間を大幅に短縮することが可能であり、顧客は、市場投入までの期間を短縮し、投資リスクを軽減することができる熟練したCDMOを求めています。その結果、製薬バイオテクノロジー産業向けの商品を設計・製造するCDMOのニーズは飛躍的に高まっています。

mRNA治療薬の開発・製造受託機関市場レポートハイライト

• 2024年にはウイルスワクチンセグメントが最大のシェアを占めます。同セグメントの成長は、ウイルス感染治療用の各種ワクチンの入手可能性と発売が増加していることに起因する（COVID-19）。
• 感染症セグメントが2024年に最大の市場シェアを占めたのは、感染症の罹患率の増加、従来型ワクチンに対するmRNAワクチンのいくつかの利点、新たな臨床研究とパイプライン分析、製薬企業と市場セグメンテーション間の生産協力の増加によるものです。
• バイオ企業の最終用途セグメントが市場を独占し、2024年には62.34%以上のシェアを占めました。このセグメントの成長を牽引しているのは、mRNAワクチン製造のためのCDMOとの提携・協力といった戦略的イニシアチブの増加です。
• アジア太平洋のmRNA治療薬の開発・製造受託機関市場は、予測期間中に大幅なCAGRで成長すると予想されます。インドや中国のような発展途上国では製薬会社や製造受託機関の数が増加しているため、アジア太平洋のは近い将来、欧州のや北米のを追い抜く可能性が高いです。

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 mRNA治療薬の開発・製造受託機関の市場変数、動向、範囲

• 市場系統の展望
  • 親市場の展望
  • 関連/補助市場展望
• 市場力学
  • 市場促進要因分析
  • 市場抑制要因分析
• 価格モデル分析
• 技術
• 市場分析ツール
  • ポーターのファイブフォース分析
  • SWOT分析によるPESTEL
  • COVID-19の影響分析

第4章 mRNA治療薬の開発・製造受託機関市場：適応症別、推定・動向分析

• mRNA治療薬の開発・製造受託機関市場、適応症別：セグメントダッシュボード
• mRNA治療薬の開発・製造受託機関市場、適応症別：変動分析
• 適応症別、2021～2033年
• 感染症
• 代謝性疾患と遺伝性疾患
• 心血管疾患と脳血管疾患

第5章 mRNA治療薬の開発・製造受託機関市場：用途別、推定・動向分析

• mRNA治療薬の開発・製造受託機関市場、用途別：セグメントダッシュボード
• mRNA治療薬の開発・製造受託機関市場、用途別：変動分析
• 用途別、2021～2033年
• ウイルスワクチン
• タンパク質補充療法
• がん免疫療法

第6章 mRNA治療薬の開発・製造受託機関市場：最終用途別、推定・動向分析

• mRNA治療薬の開発・製造受託機関市場、最終用途別：セグメントダッシュボード
• mRNA治療薬の開発・製造受託機関市場、最終用途別：変動分析
• 最終用途別、2021～2033年
• バイオテクノロジー企業
• 製薬会社
• 政府と学術研究機関

第7章 mRNA治療薬の開発・製造受託機関市場：地域別、推定・動向分析

• 地域別市場ダッシュボード
• 地域別市場シェア分析、2024年と2033年
• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • 英国
  • ドイツ
  • フランス
  • イタリア
  • スペイン
  • デンマーク
  • スウェーデン
  • ノルウェー
• アジア太平洋
  • 日本
  • 中国
  • インド
  • タイ
  • 韓国
  • オーストラリア
• ラテンアメリカ
  • ブラジル
  • アルゼンチン
• 中東・アフリカ
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦
  • クウェート

第8章 競合情勢

• 市場参入企業の分類
• 企業市場シェア/評価分析、2024年
• 企業プロファイル
  • Danaher（Aldevron）
  • Biomay AG
  • Bio-Synthesis, Inc.
  • eTheRNA
  • Kaneka Eurogentec SA
  • TriLink BioTechnologies
  • ApexBio Technology
  • BioNTech SE
  • Biocina
  • Lonza
  • Recipharm AB
  • Novo Holdings（Catalent, Inc.）
  • Samsung Biologics

List of Tables

• Table 1. List of Secondary Sources
• Table 2. List of Abbreviations
• Table 3. Global mRNA Therapeutics Contract Development & Manufacturing Organization Market Estimates and Forecasts, by Indication, 2021 - 2033 (USD Million)
• Table 4. Global mRNA Therapeutics Contract Development & Manufacturing Organization Market Estimates and Forecasts, by Application, 2021 - 2033 (USD Million)
• Table 5. Global mRNA Therapeutics Contract Development & Manufacturing Organization Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million)
• Table 6. Global mRNA Therapeutics Contract Development & Manufacturing Organization Market Estimates and Forecasts, by Region, 2021 - 2033 (USD Million)
• Table 7. North America mRNA Therapeutics Contract Development & Manufacturing Organization Market Estimates and Forecasts, by Country, 2021 - 2033 (USD Million)
• Table 8. North America mRNA Therapeutics Contract Development & Manufacturing Organization Market Estimates and Forecasts, by Indication, 2021 - 2033 (USD Million)
• Table 9. North America mRNA Therapeutics Contract Development & Manufacturing Organization Market Estimates and Forecasts, by Application, 2021 - 2033 (USD Million)
• Table 10. North America mRNA Therapeutics Contract Development & Manufacturing Organization Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million)
• Table 11. U.S. mRNA Therapeutics Contract Development & Manufacturing Organization Market Estimates and Forecasts, by Indication, 2021 - 2033 (USD Million)
• Table 12. U.S. mRNA Therapeutics Contract Development & Manufacturing Organization Market Estimates and Forecasts, by Application, 2021 - 2033 (USD Million)
• Table 13. U.S. mRNA Therapeutics Contract Development & Manufacturing Organization Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million)
• Table 14. Canada mRNA Therapeutics Contract Development & Manufacturing Organization Market Estimates and Forecasts, by Indication, 2021 - 2033 (USD Million)
• Table 15. Canada mRNA Therapeutics Contract Development & Manufacturing Organization Market Estimates and Forecasts, by Application, 2021 - 2033 (USD Million)
• Table 16. Canada mRNA Therapeutics Contract Development & Manufacturing Organization Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million)
• Table 17. Mexico mRNA Therapeutics Contract Development & Manufacturing Organization Market Estimates and Forecasts, by Indication, 2021 - 2033 (USD Million)
• Table 18. Mexico mRNA Therapeutics Contract Development & Manufacturing Organization Market Estimates and Forecasts, by Application, 2021 - 2033 (USD Million)
• Table 19. Mexico mRNA Therapeutics Contract Development & Manufacturing Organization Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million)
• Table 20. Europe mRNA Therapeutics Contract Development & Manufacturing Organization Market Estimates and Forecasts, by Country, 2021 - 2033 (USD Million)
• Table 21. Europe mRNA Therapeutics Contract Development & Manufacturing Organization Market Estimates and Forecasts, by Indication, 2021 - 2033 (USD Million)
• Table 22. Europe mRNA Therapeutics Contract Development & Manufacturing Organization Market Estimates and Forecasts, by Application, 2021 - 2033 (USD Million)
• Table 23. Europe mRNA Therapeutics Contract Development & Manufacturing Organization Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million)
• Table 24. UK mRNA Therapeutics Contract Development & Manufacturing Organization Market Estimates and Forecasts, by Indication, 2021 - 2033 (USD Million)
• Table 25. UK mRNA Therapeutics Contract Development & Manufacturing Organization Market Estimates and Forecasts, by Application, 2021 - 2033 (USD Million)
• Table 26. UK mRNA Therapeutics Contract Development & Manufacturing Organization Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million)
• Table 27. Germany mRNA Therapeutics Contract Development & Manufacturing Organization Market Estimates and Forecasts, by Indication, 2021 - 2033 (USD Million)
• Table 28. Germany mRNA Therapeutics Contract Development & Manufacturing Organization Market Estimates and Forecasts, by Application, 2021 - 2033 (USD Million)
• Table 29. Germany mRNA Therapeutics Contract Development & Manufacturing Organization Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million)
• Table 30. France mRNA Therapeutics Contract Development & Manufacturing Organization Market Estimates and Forecasts, by Indication, 2021 - 2033 (USD Million)
• Table 31. France mRNA Therapeutics Contract Development & Manufacturing Organization Market Estimates and Forecasts, by Application, 2021 - 2033 (USD Million)
• Table 32. France mRNA Therapeutics Contract Development & Manufacturing Organization Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million)
• Table 33. Italy mRNA Therapeutics Contract Development & Manufacturing Organization Market Estimates and Forecasts, by Indication, 2021 - 2033 (USD Million)
• Table 34. Italy mRNA Therapeutics Contract Development & Manufacturing Organization Market Estimates and Forecasts, by Application, 2021 - 2033 (USD Million)
• Table 35. Italy mRNA Therapeutics Contract Development & Manufacturing Organization Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million)
• Table 36. Spain mRNA Therapeutics Contract Development & Manufacturing Organization Market Estimates and Forecasts, by Indication, 2021 - 2033 (USD Million)
• Table 37. Spain mRNA Therapeutics Contract Development & Manufacturing Organization Market Estimates and Forecasts, by Application, 2021 - 2033 (USD Million)
• Table 38. Spain mRNA Therapeutics Contract Development & Manufacturing Organization Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million)
• Table 39. Denmark mRNA Therapeutics Contract Development & Manufacturing Organization Market Estimates and Forecasts, by Indication, 2021 - 2033 (USD Million)
• Table 40. Denmark mRNA Therapeutics Contract Development & Manufacturing Organization Market Estimates and Forecasts, by Therapeutics Area, 2021 - 2033 (USD Million)
• Table 41. Denmark mRNA Therapeutics Contract Development & Manufacturing Organization Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million)
• Table 42. Sweden mRNA Therapeutics Contract Development & Manufacturing Organization Market Estimates and Forecasts, by Indication, 2021 - 2033 (USD Million)
• Table 43. Sweden mRNA Therapeutics Contract Development & Manufacturing Organization Market Estimates and Forecasts, by Application, 2021 - 2033 (USD Million)
• Table 44. Sweden mRNA Therapeutics Contract Development & Manufacturing Organization Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million)
• Table 45. Norway mRNA Therapeutics Contract Development & Manufacturing Organization Market Estimates and Forecasts, by Indication, 2021 - 2033 (USD Million)
• Table 46. Norway mRNA Therapeutics Contract Development & Manufacturing Organization Market Estimates and Forecasts, by Application, 2021 - 2033 (USD Million)
• Table 47. Norway mRNA Therapeutics Contract Development & Manufacturing Organization Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million)
• Table 48. Asia Pacific mRNA Therapeutics Contract Development & Manufacturing Organization Market Estimates and Forecasts, by Country, 2021 - 2033 (USD Million)
• Table 49. Asia Pacific mRNA Therapeutics Contract Development & Manufacturing Organization Market Estimates and Forecasts, by Indication, 2021 - 2033 (USD Million)
• Table 50. Asia Pacific mRNA Therapeutics Contract Development & Manufacturing Organization Market Estimates and Forecasts, by Application, 2021 - 2033 (USD Million)
• Table 51. Asia Pacific mRNA Therapeutics Contract Development & Manufacturing Organization Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million)
• Table 52. Japan mRNA Therapeutics Contract Development & Manufacturing Organization Market Estimates and Forecasts, by Indication, 2021 - 2033 (USD Million)
• Table 53. Japan mRNA Therapeutics Contract Development & Manufacturing Organization Market Estimates and Forecasts, by Application, 2021 - 2033 (USD Million)
• Table 54. Japan mRNA Therapeutics Contract Development & Manufacturing Organization Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million)
• Table 55. China mRNA Therapeutics Contract Development & Manufacturing Organization Market Estimates and Forecasts, by Indication, 2021 - 2033 (USD Million)
• Table 56. China mRNA Therapeutics Contract Development & Manufacturing Organization Market Estimates and Forecasts, by Application, 2021 - 2033 (USD Million)
• Table 57. China mRNA Therapeutics Contract Development & Manufacturing Organization Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million)
• Table 58. India mRNA Therapeutics Contract Development & Manufacturing Organization Market Estimates and Forecasts, by Indication, 2021 - 2033 (USD Million)
• Table 59. India mRNA Therapeutics Contract Development & Manufacturing Organization Market Estimates and Forecasts, by Therapeutics Area, 2021 - 2033 (USD Million)
• Table 60. India mRNA Therapeutics Contract Development & Manufacturing Organization Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million)
• Table 61. Thailand mRNA Therapeutics Contract Development & Manufacturing Organization Market Estimates and Forecasts, by Indication, 2021 - 2033 (USD Million)
• Table 62. Thailand mRNA Therapeutics Contract Development & Manufacturing Organization Market Estimates and Forecasts, by Application, 2021 - 2033 (USD Million)
• Table 63. Thailand mRNA Therapeutics Contract Development & Manufacturing Organization Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million)
• Table 64. South Korea mRNA Therapeutics Contract Development & Manufacturing Organization Market Estimates and Forecasts, by Indication, 2021 - 2033 (USD Million)
• Table 65. South Korea mRNA Therapeutics Contract Development & Manufacturing Organization Market Estimates and Forecasts, by Application, 2021 - 2033 (USD Million)
• Table 66. South Korea mRNA Therapeutics Contract Development & Manufacturing Organization Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million)
• Table 67. Australia mRNA Therapeutics Contract Development & Manufacturing Organization Market Estimates and Forecasts, by Indication, 2021 - 2033 (USD Million)
• Table 68. Australia mRNA Therapeutics Contract Development & Manufacturing Organization Market Estimates and Forecasts, by Application, 2021 - 2033 (USD Million)
• Table 69. Australia mRNA Therapeutics Contract Development & Manufacturing Organization Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million)
• Table 70. Latin America mRNA Therapeutics Contract Development & Manufacturing Organization Market Estimates and Forecasts, by Country, 2021 - 2033 (USD Million)
• Table 71. Latin America mRNA Therapeutics Contract Development & Manufacturing Organization Market Estimates and Forecasts, by Indication, 2021 - 2033 (USD Million)
• Table 72. Latin America mRNA Therapeutics Contract Development & Manufacturing Organization Market Estimates and Forecasts, by Application, 2021 - 2033 (USD Million)
• Table 73. Latin America mRNA Therapeutics Contract Development & Manufacturing Organization Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million)
• Table 74. Brazil mRNA Therapeutics Contract Development & Manufacturing Organization Market Estimates and Forecasts, by Indication, 2021 - 2033 (USD Million)
• Table 75. Brazil mRNA Therapeutics Contract Development & Manufacturing Organization Market Estimates and Forecasts, by Application, 2021 - 2033 (USD Million)
• Table 76. Brazil mRNA Therapeutics Contract Development & Manufacturing Organization Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million)
• Table 77. Argentina mRNA Therapeutics Contract Development & Manufacturing Organization Market Estimates and Forecasts, by Indication, 2021 - 2033 (USD Million)
• Table 78. Argentina mRNA Therapeutics Contract Development & Manufacturing Organization Market Estimates and Forecasts, by Application, 2021 - 2033 (USD Million)
• Table 79. Argentina mRNA Therapeutics Contract Development & Manufacturing Organization Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million)
• Table 80. Middle East & Africa mRNA Therapeutics Contract Development & Manufacturing Organization Market Estimates and Forecasts, by Country, 2021 - 2033 (USD Million)
• Table 81. Middle East & Africa mRNA Therapeutics Contract Development & Manufacturing Organization Market Estimates and Forecasts, by Application, 2021 - 2033 (USD Million)
• Table 82. Middle East & Africa mRNA Therapeutics Contract Development & Manufacturing Organization Market Estimates and Forecasts, by Indication, 2021 - 2033 (USD Million)
• Table 83. Middle East & Africa mRNA Therapeutics Contract Development & Manufacturing Organization Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million)
• Table 84. South Africa mRNA Therapeutics Contract Development & Manufacturing Organization Market Estimates and Forecasts, by Indication, 2021 - 2033 (USD Million)
• Table 85. South Africa mRNA Therapeutics Contract Development & Manufacturing Organization Market Estimates and Forecasts, by Application, 2021 - 2033 (USD Million)
• Table 86. South Africa mRNA Therapeutics Contract Development & Manufacturing Organization Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million)
• Table 87. Saudi Arabia mRNA Therapeutics Contract Development & Manufacturing Organization Market Estimates and Forecasts, by Indication, 2021 - 2033 (USD Million)
• Table 88. Saudi Arabia mRNA Therapeutics Contract Development & Manufacturing Organization Market Estimates and Forecasts, by Application, 2021 - 2033 (USD Million)
• Table 89. Saudi Arabia mRNA Therapeutics Contract Development & Manufacturing Organization Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million)
• Table 90. UAE mRNA Therapeutics Contract Development & Manufacturing Organization Market Estimates and Forecasts, by Indication, 2021 - 2033 (USD Million)
• Table 91. UAE mRNA Therapeutics Contract Development & Manufacturing Organization Market Estimates and Forecasts, by Application, 2021 - 2033 (USD Million)
• Table 92. UAE mRNA Therapeutics Contract Development & Manufacturing Organization Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million)
• Table 93. Kuwait mRNA Therapeutics Contract Development & Manufacturing Organization Market Estimates and Forecasts, by Indication, 2021 - 2033 (USD Million)
• Table 94. Kuwait mRNA Therapeutics Contract Development & Manufacturing Organization Market Estimates and Forecasts, by Application, 2021 - 2033 (USD Million)
• Table 95. Kuwait mRNA Therapeutics Contract Development & Manufacturing Organization Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million)

List of Figures

• Fig. 1 Market research process
• Fig. 2 Information procurement
• Fig. 3 Primary research pattern
• Fig. 4 Market research approaches
• Fig. 5 Market formulation & validation
• Fig. 6 Commodity flow analysis
• Fig. 7 Value-chain-based sizing & forecasting
• Fig. 8 QFD model sizing & forecasting
• Fig. 9 Bottom-up approach
• Fig. 10 Market snapshot
• Fig. 11 Segment snapshot 1
• Fig. 12 Segment snapshot 2
• Fig. 13 Competitive landscape snapshot
• Fig. 14 Parent market outlook, 2024 (USD Billion)
• Fig. 15 Ancillary market outlook, 2024 (USD Billion)
• Fig. 16 mRNA Therapeutics Contract Development & Manufacturing Organization Market Dynamics
• Fig. 17 Porter's five forces analysis
• Fig. 18 PESTEL analysis
• Fig. 19 mRNA Therapeutics Contract Development & Manufacturing Organization Market: Indication outlook and key takeaways
• Fig. 20 mRNA Therapeutics Contract Development & Manufacturing Organization Market: Indication movement analysis
• Fig. 21 Infectious Diseases Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• Fig. 22 Metabolic & Genetic Diseases Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• Fig. 23 Cardiovascular & Cerebrovascular Diseases Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• Fig. 24 mRNA Therapeutics Contract Development & Manufacturing Organization Market: Application outlook and key takeaways
• Fig. 25 mRNA Therapeutics Contract Development & Manufacturing Organization Market: Application movement analysis
• Fig. 26 Viral Vaccines Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• Fig. 27 Protein Replacement Therapies Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• Fig. 28 Cancer Immunotherapies Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• Fig. 29 mRNA Therapeutics Contract Development & Manufacturing Organization Market: End Use outlook and key takeaways
• Fig. 30 mRNA Therapeutics Contract Development & Manufacturing Organization Market: End Use movement analysis
• Fig. 31 Biotech Companies Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• Fig. 32 Pharmaceutical companies Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• Fig. 33 Government & Academic Research Institutes Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• Fig. 34 Regional Marketplace: Key Takeaways
• Fig. 35 North America mRNA Therapeutics Contract Development & Manufacturing Organization Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• Fig. 36 Key country dynamics
• Fig. 37 U.S. mRNA Therapeutics Contract Development & Manufacturing Organization Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• Fig. 38 Key country dynamics
• Fig. 39 Canada mRNA Therapeutics Contract Development & Manufacturing Organization Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• Fig. 40 Key country dynamics
• Fig. 41 Mexico mRNA Therapeutics Contract Development & Manufacturing Organization Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• Fig. 42 Europe mRNA Therapeutics Contract Development & Manufacturing Organization Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• Fig. 43 Key country dynamics
• Fig. 44 UK mRNA Therapeutics Contract Development & Manufacturing Organization Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• Fig. 45 Key country dynamics
• Fig. 46 Germany mRNA Therapeutics Contract Development & Manufacturing Organization Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• Fig. 47 Key country dynamics
• Fig. 48 France mRNA Therapeutics Contract Development & Manufacturing Organization Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• Fig. 49 Key country dynamics
• Fig. 50 Italy mRNA Therapeutics Contract Development & Manufacturing Organization Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• Fig. 51 Key country dynamics
• Fig. 52 Spain mRNA Therapeutics Contract Development & Manufacturing Organization Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• Fig. 53 Key country dynamics
• Fig. 54 Denmark mRNA Therapeutics Contract Development & Manufacturing Organization Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• Fig. 55 Key country dynamics
• Fig. 56 Sweden mRNA Therapeutics Contract Development & Manufacturing Organization Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• Fig. 57 Key country dynamics
• Fig. 58 Norway mRNA Therapeutics Contract Development & Manufacturing Organization Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• Fig. 59 Asia Pacific mRNA Therapeutics Contract Development & Manufacturing Organization Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• Fig. 60 Key country dynamics
• Fig. 61 Japan mRNA Therapeutics Contract Development & Manufacturing Organization Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• Fig. 62 Key country dynamics
• Fig. 63 China mRNA Therapeutics Contract Development & Manufacturing Organization Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• Fig. 64 Key country dynamics
• Fig. 65 India mRNA Therapeutics Contract Development & Manufacturing Organization Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• Fig. 66 Key country dynamics
• Fig. 67 Thailand mRNA Therapeutics Contract Development & Manufacturing Organization Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• Fig. 68 Key country dynamics
• Fig. 69 South Korea mRNA Therapeutics Contract Development & Manufacturing Organization Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• Fig. 70 Key country dynamics
• Fig. 71 Australia mRNA Therapeutics Contract Development & Manufacturing Organization Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• Fig. 72 Latin America mRNA Therapeutics Contract Development & Manufacturing Organization Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• Fig. 73 Key country dynamics
• Fig. 74 Brazil mRNA Therapeutics Contract Development & Manufacturing Organization Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• Fig. 75 Key country dynamics
• Fig. 76 Argentina mRNA Therapeutics Contract Development & Manufacturing Organization Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• Fig. 77 MEA mRNA Therapeutics Contract Development & Manufacturing Organization Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• Fig. 78 Key country dynamics
• Fig. 79 South Africa mRNA Therapeutics Contract Development & Manufacturing Organization Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• Fig. 80 Key country dynamics
• Fig. 81 Saudi Arabia mRNA Therapeutics Contract Development & Manufacturing Organization Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• Fig. 82 Key country dynamics
• Fig. 83 UAE mRNA Therapeutics Contract Development & Manufacturing Organization Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• Fig. 84 Key country dynamics
• Fig. 85 Kuwait mRNA Therapeutics Contract Development & Manufacturing Organization Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• Fig. 86 Key company categorization
• Fig. 87 Service heat map analysis
• Fig. 88 Strategic framework

mRNA Therapeutics Contract Development & Manufacturing Organization Market Growth & Trends:

The global mRNA therapeutics contract development & manufacturing organization market size is estimated to reach USD 14.75 billion by 2033, expanding at a CAGR of 15.22% from 2025 to 2033, according to a new report by Grand View Research, Inc. Growing technological advancements in mRNA and cellular delivery systems, coupled with their cost effectiveness, manufacturing simplicity, and ability to target previously undruggable pathways, have limitless potential to revolutionize medicine. This could represent lucrative growth opportunities for the market. Increasing R&D investments to develop mRNA therapeutics and a strong product pipeline are also propelling the market's growth. For instance, Moderna shared that R&D expenses for the fourth quarter of 2023 increased by 16% to USD 1.4 billion compared to the same quarter of 2022.

The R&D spending was driven by increased clinical manufacturing activities, with the company's Cytomegalovirus (CMV) vaccine, RSV vaccine, and combination vaccine against COVID-19 & flu, as well as its individualized neoantigen therapy. Such factors are expected to boost research efforts in mRNA therapeutics. In addition, developing novel therapeutics to address unmet medical needs is altering the product market. The rise in molecular complexity drives the need for in-depth knowledge in research and manufacturing services, as well as the technology to enable sustainable expression and scale-up of novel molecular formats. Platform technologies, such as those for bioconjugation or the creation of bispecific antibodies, can drastically shorten development and production times, and customers are looking for skilled CDMOs who can assist them shorten the time to market and reducing investment risk. Consequently, the need for CDMOs to design and produce goods for the pharmaceutical and biotechnology industries is growing exponentially.

mRNA Therapeutics Contract Development & Manufacturing Organization Market Report Highlights:

• The viral vaccines segment accounted for the largest share in 2024. Growth in the segment can be attributed to the rising availability and launch of various vaccines for the treatment of viral infection (COVID-19)
• The infectious diseases segment held the largest market share in 2024 due to the growing incidence of infectious diseases, several advantages of mRNA vaccine over conventional vaccines, emerging clinical studies & pipeline analysis, and increasing collaboration between pharmaceutical companies & CDMO for production
• The biotech companies end-use segment dominated the market and accounted for a share of more than 62.34% in 2024. The segment growth is driven by increasing strategic initiatives, such as partnerships & collaborations with CDMOs, to manufacture mRNA vaccines
• The mRNA therapeutics contract development & manufacturing organization market in Asia Pacific is expected to grow at a significant CAGR over the forecast period. Due to the rising number of pharmaceutical companies and contract manufacturing organizations in developing countries like India and China, Asia Pacific is likely to overtake Europe and North America in the near future.

Table of Contents

Chapter 1. Research Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Indication
  • 1.2.2. Application
  • 1.2.3. End Use
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased Database
  • 1.4.2. GVR's Internal Database
  • 1.4.3. Secondary Sources
  • 1.4.4. Primary Research
• 1.5. Information Or Data Analysis
  • 1.5.1. Data Analysis Models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity Flow Analysis
  • 1.7.2. Value-Chain-Based Sizing & Forecasting
  • 1.7.3. Multivariate Model Analysis
• 1.8. List Of Secondary Sources
• 1.9. List Of Abbreviations
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
• 2.3. Competitive Insights

Chapter 3. mRNA Therapeutics Contract Development & Manufacturing Organization Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent Market Outlook
  • 3.1.2. Related/Ancillary Market Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
    • 3.2.1.1. Rapid adoption of mRNA in vaccine development
    • 3.2.1.2. Multiple research efforts on mRNA therapeutics
    • 3.2.1.3. Major funding for mRNA research
  • 3.2.2. Market Restraint Analysis
    • 3.2.2.1. Availability of low-cost substitute therapies
    • 3.2.2.2. High research cost
• 3.3. Pricing Model Analysis
• 3.4. Technology Landscape
• 3.5. Market Analysis Tools
  • 3.5.1. Porter's Five Force Analysis
  • 3.5.2. PESTEL by SWOT Analysis
  • 3.5.3. COVID-19 Impact Analysis

Chapter 4. mRNA Therapeutics Contract Development & Manufacturing Organization Market: Indication Estimates & Trend Analysis

• 4.1. mRNA Therapeutics Contract Development & Manufacturing Organization Market, By Indication: Segment Dashboard
• 4.2. mRNA Therapeutics Contract Development & Manufacturing Organization Market, By Indication: Movement Analysis
• 4.3. mRNA Therapeutics Contract Development & Manufacturing Organization Market Estimates & Forecasts, By Indication, 2021 - 2033 (USD Million)
• 4.4. Infectious Diseases
  • 4.4.1. Infectious Diseases Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 4.5. Metabolic & Genetic Diseases
  • 4.5.1. Metabolic & Genetic Diseases Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 4.6. Cardiovascular & Cerebrovascular Diseases
  • 4.6.1. Cardiovascular & Cerebrovascular Diseases Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 5. mRNA Therapeutics Contract Development & Manufacturing Organization Market: Application Estimates & Trend Analysis

• 5.1. mRNA Therapeutics Contract Development & Manufacturing Organization Market, By Application: Segment Dashboard
• 5.2. mRNA Therapeutics Contract Development & Manufacturing Organization Market, By Application: Movement Analysis
• 5.3. mRNA Therapeutics Contract Development & Manufacturing Organization Market Estimates & Forecasts, By Application, 2021 - 2033 (USD Million)
• 5.4. Viral Vaccines
  • 5.4.1. Viral Vaccines Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.5. Protein Replacement Therapies
  • 5.5.1. Protein Replacement Therapies Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.6. Cancer Immunotherapies
  • 5.6.1. Cancer Immunotherapies Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 6. mRNA Therapeutics Contract Development & Manufacturing Organization Market: End Use Estimates & Trend Analysis

• 6.1. mRNA Therapeutics Contract Development & Manufacturing Organization Market, By End Use: Segment Dashboard
• 6.2. mRNA Therapeutics Contract Development & Manufacturing Organization Market, By End Use: Movement Analysis
• 6.3. mRNA Therapeutics Contract Development & Manufacturing Organization Market Estimates & Forecasts, By End Use, 2021 - 2033 (USD Million)
• 6.4. Biotech Companies
  • 6.4.1. Biotech Companies Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.5. Pharmaceutical companies
  • 6.5.1. Pharmaceutical companies Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.6. Government & Academic Research Institutes
  • 6.6.1. Government & Academic Research Institutes Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 7. mRNA Therapeutics Contract Development & Manufacturing Organization Market: Regional Estimates & Trend Analysis

• 7.1. Regional Market Dashboard
• 7.2. Regional Market Share Analysis, 2024 & 2033
• 7.3. North America
  • 7.3.1. North America Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.3.2. U.S
    • 7.3.2.1. Key Country Dynamics
    • 7.3.2.2. Competitive Scenario
    • 7.3.2.3. Regulatory Framework
    • 7.3.2.4. U.S. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.3.3. Canada
    • 7.3.3.1. Key Country Dynamics
    • 7.3.3.2. Competitive Scenario
    • 7.3.3.3. Regulatory Framework
    • 7.3.3.4. Canada Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.3.4. Mexico
    • 7.3.4.1. Key Country Dynamics
    • 7.3.4.2. Competitive Scenario
    • 7.3.4.3. Regulatory Framework
    • 7.3.4.4. Mexico Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 7.4. Europe
  • 7.4.1. Europe Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.4.2. UK
    • 7.4.2.1. Key Country Dynamics
    • 7.4.2.2. Competitive Scenario
    • 7.4.2.3. Regulatory Framework
    • 7.4.2.4. UK Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.4.3. Germany
    • 7.4.3.1. Key Country Dynamics
    • 7.4.3.2. Competitive Scenario
    • 7.4.3.3. Regulatory Framework
    • 7.4.3.4. Germany Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.4.4. France
    • 7.4.4.1. Key Country Dynamics
    • 7.4.4.2. Competitive Scenario
    • 7.4.4.3. Regulatory Framework
    • 7.4.4.4. France Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.4.5. Italy
    • 7.4.5.1. Key Country Dynamics
    • 7.4.5.2. Competitive Scenario
    • 7.4.5.3. Regulatory Framework
    • 7.4.5.4. Italy Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.4.6. Spain
    • 7.4.6.1. Key Country Dynamics
    • 7.4.6.2. Competitive Scenario
    • 7.4.6.3. Regulatory Framework
    • 7.4.6.4. Spain Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.4.7. Denmark
    • 7.4.7.1. Key Country Dynamics
    • 7.4.7.2. Competitive Scenario
    • 7.4.7.3. Regulatory Framework
    • 7.4.7.4. Denmark Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.4.8. Sweden
    • 7.4.8.1. Key Country Dynamics
    • 7.4.8.2. Competitive Scenario
    • 7.4.8.3. Regulatory Framework
    • 7.4.8.4. Sweden Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.4.9. Norway
    • 7.4.9.1. Key Country Dynamics
    • 7.4.9.2. Competitive Scenario
    • 7.4.9.3. Regulatory Framework
    • 7.4.9.4. Norway Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 7.5. Asia Pacific
  • 7.5.1. Asia Pacific Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.5.2. Japan
    • 7.5.2.1. Key Country Dynamics
    • 7.5.2.2. Competitive Scenario
    • 7.5.2.3. Regulatory Framework
    • 7.5.2.4. Japan Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.5.3. China
    • 7.5.3.1. Key Country Dynamics
    • 7.5.3.2. Competitive Scenario
    • 7.5.3.3. Regulatory Framework
    • 7.5.3.4. China Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.5.4. India
    • 7.5.4.1. Key Country Dynamics
    • 7.5.4.2. Competitive Scenario
    • 7.5.4.3. Regulatory Framework
    • 7.5.4.4. India Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.5.5. Thailand
    • 7.5.5.1. Key Country Dynamics
    • 7.5.5.2. Competitive Scenario
    • 7.5.5.3. Regulatory Framework
    • 7.5.5.4. Thailand Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.5.6. South Korea
    • 7.5.6.1. Key Country Dynamics
    • 7.5.6.2. Competitive Scenario
    • 7.5.6.3. Regulatory Framework
    • 7.5.6.4. South Korea Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.5.7. Australia
    • 7.5.7.1. Key Country Dynamics
    • 7.5.7.2. Competitive Scenario
    • 7.5.7.3. Regulatory Framework
    • 7.5.7.4. Australia Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 7.6. Latin America
  • 7.6.1. Latin America Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.6.2. Brazil
    • 7.6.2.1. Key Country Dynamics
    • 7.6.2.2. Competitive Scenario
    • 7.6.2.3. Regulatory Framework
    • 7.6.2.4. Brazil Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.6.3. Argentina
    • 7.6.3.1. Key Country Dynamics
    • 7.6.3.2. Competitive Scenario
    • 7.6.3.3. Regulatory Framework
    • 7.6.3.4. Argentina Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 7.7. MEA
  • 7.7.1. MEA Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.7.2. South Africa
    • 7.7.2.1. Key Country Dynamics
    • 7.7.2.2. Competitive Scenario
    • 7.7.2.3. Regulatory Framework
    • 7.7.2.4. South Africa Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.7.3. Saudi Arabia
    • 7.7.3.1. Key Country Dynamics
    • 7.7.3.2. Competitive Scenario
    • 7.7.3.3. Regulatory Framework
    • 7.7.3.4. Saudi Arabia Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.7.4. UAE
    • 7.7.4.1. Key Country Dynamics
    • 7.7.4.2. Competitive Scenario
    • 7.7.4.3. Regulatory Framework
    • 7.7.4.4. UAE Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.7.5. Kuwait
    • 7.7.5.1. Key Country Dynamics
    • 7.7.5.2. Competitive Scenario
    • 7.7.5.3. Regulatory Framework
    • 7.7.5.4. Kuwait Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 8. Competitive Landscape

• 8.1. Market Participant Categorization
• 8.2. Company Market Share/Assessment Analysis, 2024
• 8.3. Company Profiles
  • 8.3.1. Danaher (Aldevron)
    • 8.3.1.1. Company Overview
    • 8.3.1.2. Financial Performance
    • 8.3.1.3. Service Benchmarking
    • 8.3.1.4. Strategic Initiatives
  • 8.3.2. Biomay AG
    • 8.3.2.1. Company Overview
    • 8.3.2.2. Financial Performance
    • 8.3.2.3. Service Benchmarking
    • 8.3.2.4. Strategic Initiatives
  • 8.3.3. Bio-Synthesis, Inc.
    • 8.3.3.1. Company Overview
    • 8.3.3.2. Financial Performance
    • 8.3.3.3. Service Benchmarking
    • 8.3.3.4. Strategic Initiatives
  • 8.3.4. eTheRNA
    • 8.3.4.1. Company Overview
    • 8.3.4.2. Financial Performance
    • 8.3.4.3. Service Benchmarking
    • 8.3.4.4. Strategic Initiatives
  • 8.3.5. Kaneka Eurogentec S.A.
    • 8.3.5.1. Company Overview
    • 8.3.5.2. Financial Performance
    • 8.3.5.3. Service Benchmarking
    • 8.3.5.4. Strategic Initiatives
  • 8.3.6. TriLink BioTechnologies
    • 8.3.6.1. Company Overview
    • 8.3.6.2. Financial Performance
    • 8.3.6.3. Service Benchmarking
    • 8.3.6.4. Strategic Initiatives
  • 8.3.7. ApexBio Technology
    • 8.3.7.1. Company Overview
    • 8.3.7.2. Financial Performance
    • 8.3.7.3. Service Benchmarking
    • 8.3.7.4. Strategic Initiatives
  • 8.3.8. BioNTech SE
    • 8.3.8.1. Company Overview
    • 8.3.8.2. Financial Performance
    • 8.3.8.3. Service Benchmarking
    • 8.3.8.4. Strategic Initiatives
  • 8.3.9. Biocina
    • 8.3.9.1. Company Overview
    • 8.3.9.2. Financial Performance
    • 8.3.9.3. Service Benchmarking
    • 8.3.9.4. Strategic Initiatives
  • 8.3.10. Lonza
    • 8.3.10.1. Company Overview
    • 8.3.10.2. Financial Performance
    • 8.3.10.3. Service Benchmarking
    • 8.3.10.4. Strategic Initiatives
  • 8.3.11. Recipharm AB
    • 8.3.11.1. Company Overview
    • 8.3.11.2. Financial Performance
    • 8.3.11.3. Service Benchmarking
    • 8.3.11.4. Strategic Initiatives
  • 8.3.12. Novo Holdings (Catalent, Inc.)
    • 8.3.12.1. Company Overview
    • 8.3.12.2. Financial Performance
    • 8.3.12.3. Service Benchmarking
    • 8.3.12.4. Strategic Initiatives
  • 8.3.13. Samsung Biologics
    • 8.3.13.1. Company Overview
    • 8.3.13.2. Financial Performance
    • 8.3.13.3. Service Benchmarking
    • 8.3.13.4. Strategic Initiatives